Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Nancy L. Bartlett, MD, Christopher A. Yasenchak, MD, Robert B. Sims, MD, Grzegorz S. Nowakowski, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136400

Published: 2020

Journal Articles

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Jerome Goldschmidt, MD, Ralph V. Boccia, MD, Vivian J.M. Cline, Mariana Sacchi, MD, Andres Forero-Torres, Robert B. Sims, MD, Jingmin Liu, Jonathan W. Friedberg, MD MSSc

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136583

Published: 2020

Journal Articles

Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective

Christopher A. Yasenchak, MD, Jamyia Clark, PhD MPH, Nicholas Liu, PharmD, April Beeks, MPH, Michelle A. Fanale, MD, Nicholas Robert, MDM, Kristina Yu-Isenberg, PhD MPH, RPh

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140698

Published: 2020

Journal Articles

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Robert M. Rifkin, MD, Sudhir Manda, MD, Stephen J Noga, MD PhD, Habte A Yimer, MD, Saulius K. Girnius, MD, Ruemu Ejedafeta Birhiray, MD, Christopher A. Yasenchak, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 1882.

https://doi.org/10.1182/blood-2019-124747

Published: 2019

Journal Articles

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Trevor Newhook, MS, Linda Ho, Matthew Mei, MD

Blood (2019) 134 (Supplement_1): 2852.

https://doi.org/10.1182/blood-2019-122968

Published: 2019

Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 237.

https://doi.org/10.1182/blood-2019-124866

Published: 2019

Journal Articles

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Ravi Vij, MBBS, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Catherine Davis, PharmD, David J. Kuter, MD

Blood (2018) 132 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2018-99-112074

Published: 2018

Journal Articles

Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy

Clara Chen, PhD BS, MS, Ravi Potluri, Hemanth Kanakamedala, Eros Papademetriou, Christopher A. Yasenchak, MD, Sandip Ranjan, Hitesh Bhandari, Jasdeep Mann, Catherine Davis

Blood (2017) 130 (Supplement 1): 3127.

https://doi.org/10.1182/blood.V130.Suppl_1.3127.3127

Published: 2017

Journal Articles

Clinical Profiles, Treatment Characteristics and Outcomes Among Newly Diagnosed Hodgkin Lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting

Christopher A. Yasenchak, MD, Joseph Feliciano, PharmD, Kathleen M. Aguilar, MPH, Jamyia Clark, MPH, E Susan Amirian, PhD MS, Akshara Richhariya, PhD

Blood (2017) 130 (Supplement 1): 5177.

https://doi.org/10.1182/blood.V130.Suppl_1.5177.5177

Published: 2017

Journal Articles

Economic Burden in US Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin or Chemotherapy after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Karissa Johnston, PhD, Shelagh Szabo, MSc, Joseph M Connors, MD, Christopher A. Yasenchak, MD

Blood (2017) 130 (Supplement 1): 4705.

https://doi.org/10.1182/blood.V130.Suppl_1.4705.4705

Published: 2017

Journal Articles

Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings

Ravi Potluri, Hemanth Kanakamedala, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Sandip Ranjan, Eros Papademetriou, Hitesh Bhandari, Jasdeep Mann, Catherine Davis

Blood (2017) 130 (Supplement 1): 1844.

https://doi.org/10.1182/blood.V130.Suppl_1.1844.1844

Published: 2017

Journal Articles

Side Effects and Supportive Care in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated in Later Lines of Therapy: A Pilot Analysis Conducted in 4 Countries

Clara Chen, PhD BS, MS, Katherine Byrne, Pam Hallworth, Christopher A. Yasenchak, MD

Blood (2017) 130 (Supplement 1): 5653.

https://doi.org/10.1182/blood.V130.Suppl_1.5653.5653

Published: 2017

Journal Articles

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Christopher A. Yasenchak, MD, Jakub Svoboda, MD, Sarah M Larson, MD, Don A Stevens, MD, Srikanth Gajavelli, MD, Trong Kim Le, Philippe Armand, MD PhD

Blood (2017) 130 (Supplement 1): 5626.

https://doi.org/10.1182/blood.V130.Suppl_1.5626.5626

Published: 2017

Journal Articles

Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Christopher A. Yasenchak, MD, Ahmad Halwani, MD, Ranjana Advani, Stephen Ansell, MD PhD, Lihua Elizabeth Budde, MD PhD, John M. Burke, MD, Charles M. Farber, MD PhD, Beata Holkova, MD, Luis E. Fayad, MD, Kathryn S. Kolibaba, MD, Mark Knapp, MD, Martha Li, PhD, Thomas J. Manley, MD, Dipti Patel-Donnelly, MD, Mahesh Seetharam, MD, Habte A. Yimer, MD, Nancy L Bartlett, MD

Blood (2015) 126 (23): 814.

https://doi.org/10.1182/blood.V126.23.814.814

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Julie Di Paolo, PhD, Clarence Eng, MPH, Jing Hu, PhD, Jing He, Anita Reddy, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 4152.

https://doi.org/10.1182/blood.V126.23.4152.4152

Published: 2015

Journal Articles

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Jeff P. Sharman, MD, Andrei R. Shustov, MD, Mitchell R. Smith, MD PhD, Thomas E. Boyd, MD, Christopher Hagenstad, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Jing Hu, PhD, Anita Reddy, PhD, Siddhartha Mitra, MDPhD, Christopher A. Yasenchak, MD, Farrukh T. Awan, MD MS

Blood (2015) 126 (23): 1744.

https://doi.org/10.1182/blood.V126.23.1744.1744

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Clarence Eng, MPH, Jing He, Jing Hu, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 1545.

https://doi.org/10.1182/blood.V126.23.1545.1545

Published: 2015

Journal Articles

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Christopher A. Yasenchak, MD, Andres Forero-Torres, Vivian Jean Mikao Cline-Burkhardt, Rodolfo E Bordoni, MD, Dipti Patel-Donnelly, MD, Patrick J. Flynn, MD, Robert Chen, Abraham Fong, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 587.

https://doi.org/10.1182/blood.V126.23.587.587

Published: 2015

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Michael J. Hawkins, MD, Steve Abella, MD, Meihua Wu, PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 4419.

https://doi.org/10.1182/blood.V124.21.4419.4419

Published: 2014

Journal Articles

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 294.

https://doi.org/10.1182/blood.V124.21.294.294

Published: 2014

NARROW

Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy

Clinical Profiles, Treatment Characteristics and Outcomes Among Newly Diagnosed Hodgkin Lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting

Economic Burden in US Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin or Chemotherapy after Failure of Autologous Hematopoietic Cell Transplantation

Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings

Side Effects and Supportive Care in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated in Later Lines of Therapy: A Pilot Analysis Conducted in 4 Countries

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL)

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only